A new steroidal glycoside from the seeds of Hyoscyamus niger

The influence of propolis plus Hyoscyamus niger L. against COVID-19: A phase II, multicenter, placebo-controlled, randomized trial

The incubation period of COVID-19 symptoms, along with the proliferation and high transmission rate of the SARS-CoV-2 virus, is the cause of an uncontrolled epidemic worldwide. Vaccination is the front line of prevention, and antiinflammatory and antiviral drugs are the treatment of this disease. In addition, some herbal therapy approaches can be a good way to deal with this disease. The aim of this study was to evaluate the effect of propolis syrup with Hyoscyamus niger L. extract in hospitalized patients with COVID-19 with acute disease conditions in a double-blinded approach. The study was performed on 140 patients with COVID-19 in a double-blind, randomized, and multicentral approach. The main inclusion criterion was the presence of a severe type of COVID-19 disease. The duration of treatment with syrup was 6 days and 30 CC per day in the form of three meals. On Days 0, 2, 4, and 6, arterial blood oxygen levels, C-reactive protein (CRP), erythrocyte sedimentation rate, and white blood cell, as well as the patient's clinical symptoms such as fever and chills, cough and shortness of breath, chest pain, and other symptoms, were recorded and analyzed. Propolis syrup with H. niger L. significantly reduces cough from the second day, relieving shortness of breath on the fourth day, and significantly reduces CRP, weakness, and lethargy, as well as significantly increased arterial blood oxygen pressure on the sixth day compared to the placebo group (p < 0.05). The results in patients are such that in the most severe conditions of the disease 80% < SpO2 (oxygen saturation), the healing process of the syrup on reducing CRP and increasing arterial blood oxygen pressure from the fourth day is significantly different compared with the placebo group (p < 0.05). The use of syrup is associated with a reduction of 3.6 days in the hospitalization period compared with the placebo group. Propolis syrup with H. niger L. has effectiveness in the viral and inflammatory phases on clinical symptoms and blood parameters and arterial blood oxygen levels of patients with COVID-19. Also, it reduces referrals to the intensive care unit and mortality in hospitalized patients with COVID-19. So, this syrup promises to be an effective treatment in the great challenge of COVID-19.

The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial

The outbreak of Coronavirus disease 2019 (COVID‐19) has caused a global health crisis. Nevertheless, no antiviral treatment has yet been proven effective for treating COVID‐19 and symptomatic supportive cares have been the most common treatment. Therefore, the present study was designed to evaluate the effects of propolis and Hyoscyamus niger L. extract in patients with COVID‐19. This randomized clinical trial was conducted on 50 cases referred to Akhavan and Sepehri Clinics, Kashan university of medical sciences, Iran. Subjects were divided into two groups (intervention and placebo). This syrup (containing 1.6 mg of methanolic extract along with 450 mg of propolis per 10 mL) was administered three times a day to each patient for 6 days. The clinical symptoms of COVID‐19 such as: dry cough, shortness of breath, sore throat, chest pain, fever, dizziness, headache, abdominal pain, and diarrhea were reduced with propolis plus Hyoscyamus niger L. extract than the placebo group. However, the administration of syrup was not effective in the control of nausea and vomiting. In conclusion, syrup containing propolis and Hyoscyamus niger L. extract had beneficial effects in ameliorating the signs and symptoms of COVID‐19 disease, in comparison with placebo groups.

Toxicological study of various crude extracts of Hyoscyamus gallagheri native to Oman

•

To prepare different polarities crude extracts of Hyoscyamus gallagheri.

•

To determine cytotoxic activity of the selected plant crude extracts.

•

To isolate and characterize compounds of the selected plant crude extracts.

•

To evaluate of cytotoxic activity of the isolated pure compounds.

•

The pure compounds could be used as chemotherapy agent.

Cancer is considered a major health issue all over the world for its high morbidity and mortality. Naturally obtained anticancer compounds have comparatively less side-effects, thus it remains a major focus for research. Hyoscyamus gallagheri (H. gallagheri), is one of the plants which have a useful source of bioactive metabolites. The present study is based on preparing plant extracts from the aerial parts of the herbal drug H. gallagheri with various polarities, determining their cytotoxicity and isolating the major cytotoxic compound from the highest active extract. A methanol extract was prepared by the Soxhlet extraction method. Then, it was processed with solvents of increasing polarities. Later, the extracts were evaluated for their cytotoxic activity by brine shrimp lethality assay (BSLA). The highest mass obtained was ethyl acetate and the highest cytotoxicity activity was observed in the ethyl acetate extract, While the lowest was water extract. Ethyl acetate extract was processed for isolation of cytotoxic compounds by different chromatographic methods to give nine fractions which were evaluated by BSLA. Among all, fractions No. 2, 3 and 4 showed significant activity against BSLA and the fractions were purified using preparative thin-layer chromatography (PTLC) to give four compounds (1–4). Only compound 1 showed high purity and appropriateness for NMR analysis. The compound was identified, and the structure was elucidated using 1D and 2D spectroscopy and was found to be 5,7,2′,3′,4′ pentahydroxyflavanone (1). In conclusion, the isolated bioactive compound could be used as an anticancer agent.